Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Cognitive Dysfunction (CD) can occur in Systemic Lupus Erythematosus (SLE) before the occurrence of Neuropsychiatric Lupus Erythematosus (NPSLE). Given the reversibility and fluctuation of SLE-related CD, the research for possible predictors is of great significance for early detection and intervention.
Objective: We sought to determine the prevalence, involved domains, and possible predictors of CD in SLE patients.
Methods: We conducted a retrospective cross-sectional study at Nanfang Hospital from 2018 to 2019. A total of 78 SLE patients were recruited. The Montreal Cognitive Assessment (MoCA) scale was used to screen cognitive function. Demographic, clinical, and laboratory characteristics were collected. The serum anti-methyl-d-aspartate receptor (anti-NMDAR) antibody and S100β were measured by enzyme-linked immunosorbent assay (ELISA). Multivariate logistic regression analysis and ROC curve were used to assess the predictor of SLE-related CD.
Results: Of 78 recruited patients,53 (67.9%) had CD. It mainly involved delayed recall, abstract generalization, verbal repetition, and fluency. The disease activity index (SLEDAI) was not associated with SLE-related CD ( > 0.05). Multivariate logistic regression showed that an increase in each year of education there was a decrease in the likelihood of CD (OR 0.261, CI 0.080-0.857, = 0.027) whereas with each unit increase in serum anti-NMDAR antibody there was an increased likelihood of SLE-related CD (OR 1.568, CI 1.073-2.292, = 0.020).
Conclusion: The prevalence of SLE-related CD was 67.9% in our study and SLE-related CD was not associated with disease activity. Serum anti-NMDAR antibody can be used as a predictor for SLE-related CD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0961203320958061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case Report: Sequential treatment with rituximab and belimumab in a pediatric patient of type 1 diabetes mellitus complicated with systemic lupus erythematosus.
Front Pediatr
August 2025
Department of Rheumatology and Immunology, Tianjin Children's Hospital (Children's Hospital, Tianjin University), Tianjin Key Laboratory of Birth Defects for Prevention and Treatment, Tianjin, China.
Type 1 diabetes mellitus (T1DM) and systemic lupus erythematosus (SLE) are both autoimmune diseases influenced by multiple genetic and environmental factors, but rarely coexist. This case describes a 13-year-old girl with early onset of T1DM who was diagnosed with SLE 12 years later, highlighting diagnostic and therapeutic challenges, particularly in distinguishing kidney involvement and management without exacerbating hyperglycemia. The patient presented with edema of the eyelids and lower limbs.
View Article and Find Full Text PDFNeutrophilic Urticarial Dermatosis in Systemic Lupus Erythematosus: A Diagnostic Challenge.
Cureus
September 2025
Dermatology, Temple University Hospital, Philadelphia, USA.
Neutrophilic urticarial dermatosis (NUD) is a rare condition that clinically resembles urticaria but is distinguished histopathologically. Given the overlap of clinical and histopathologic features between NUD, urticaria, and urticarial vasculitis (UV), distinguishing between these diagnoses is crucial, as their treatments differ significantly. A 47-year-old woman with systemic lupus erythematosus (SLE) presented with a mildly pruritic, burning rash for one week.
View Article and Find Full Text PDFA Therapeutic Tightrope: Managing Coexisting Crohn Disease and Systemic Lupus Erythematosus With Risankizumab.
ACG Case Rep J
September 2025
Department of Rheumatology, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
The coexistence of systemic lupus erythematosus (SLE) and Crohn disease (CD) is rare and presents significant diagnostic and therapeutic challenges due to overlapping clinical, radiologic, and histologic features. We present a 24-year-old woman with SLE, chronic immune thrombocytopenic purpura, and newly diagnosed CD treated with risankizumab, an interleukin-23 inhibitor approved for CD. She achieved complete clinical and radiologic remission of CD without SLE flares over 12 months.
View Article and Find Full Text PDF[Important medical-dental interactions. Oral manifestations of systemic auto-immune diseases].
Ned Tijdschr Tandheelkd
September 2025
The Department of Oral and Maxillofacial Surgery, University Medical Center Groningen (UMCG), The Netherlands.
Systemic auto-immune diseases are relatively common. This article describes the oral manifestations of disorders that might be seen in patients with the most prevalent auto-immune diseases, specifically rheumatoid arthritis, systemic lupus erythematosus and Sjögren's disease. The article gives guidelines for dentists and other carers within the oral care system for this category of patients.
View Article and Find Full Text PDFPharmacological insights into gut microbiota modulation in systemic lupus erythematosus: Mechanisms, treatment strategies, and clinical implications.
J Pharmacol Exp Ther
July 2025
Department of Pharmacy Practice, Parul Institute of Pharmacy & Research, Parul University, Limda, Waghodia, Vadodara, Gujarat, India. Electronic address:
Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by widespread inflammation and immune system dysregulation. Recent research suggests that the gut microbiota may play a role in the development of SLE by modulating immune system responses, affecting cytokine production, and altering the activity of T and B cells lymphocytes. As a result, there is a growing interest in microbiota-targeted therapies, including probiotics, dietary changes, and fecal microbiota transplantation.
View Article and Find Full Text PDF